
Astria Therapeutics (ATXS) Stock Forecast & Price Target
Astria Therapeutics (ATXS) Analyst Ratings
Bulls say
Astria Therapeutics is positioned positively due to the well-tolerated nature of its product candidates, particularly STAR-0310, which has demonstrated a wider therapeutic window and the potential for greater efficacy than earlier OX40 antibodies. The anticipated synergy with BioCryst’s existing commercial infrastructure is expected to drive operating profits from its assets, particularly following the launch of navenibart in the hereditary angioedema market. Additionally, the company enjoys a large commercial market opportunity, alongside significant upcoming news flow, which is likely to support strategic growth and enhance the overall pipeline.
Bears say
Astria Therapeutics Inc faces significant challenges that contribute to a negative outlook regarding its stock. The company is at risk of failed or inconclusive clinical trials for its product candidates, STAR-0215 and STAR-0310, which could hinder progress in drug development. Additionally, there are concerns about the company's ability to secure adequate funding, which is critical for continuing operations and reaching clinical milestones, further exacerbating uncertainties surrounding its valuation.
This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Astria Therapeutics (ATXS) Analyst Forecast & Price Prediction
Start investing in Astria Therapeutics (ATXS)
Order type
Buy in
Order amount
Est. shares
0 shares